CAS 76272-56-5
:Endo-9-Metil-9-Azabiciclo [3,3,1]-Nonan-3-Amina
- Endo-3-Amine-9-Methyl-9-Azabicyclo[3,3,1]Nonane
- Endo-3-amino-9-methyl-9-azabicyclo[3,3,1]nonane
- Endo-9-Methyl-9-Azabicyclo[3,3,1] nonane-3-Amine
- 9-Methyl-9-Azabicyclo[3.3.1]Nonan-3-Amine
- 9-Methyl-9-Azabicyclo[3.3.1]Nonan-1-Amine
- Endo-9-methyl-9-azabicyclo[3,3,1]-nonan-3-amine
- endo-9-methyl-9-azabicyclo[3,3,1]nonan-3-amine
- 9-Methyl-9-azabicyclo[3.3.1]nonylamine
- ENDO-3-AMINE-9-METHYL-9-AZABICYCLO[3,3,1]NONAN
- Endo-9-Methyl-9-Azabicyclo-3,3,1-Nonan-3-Amine(ForGranisetronHcl)
- EMANA
- b-3-Amino-9-methyl-9-azabicyclo(3.3.1)-nonane, Granisetron Impurity E (free base)
- 1-AMINO-9-METHYL-9-AZABICYCLO[3,3,1]-NONANE
- Endo-9-Methy-9-Azabicyclo[3,31]Nonan-3-Amine
- ENDO-3-AMINE-9-METHYL-AZABICYCLO[3.3.1] NONANE
- endo-9-Methyl-9-azabicyclo[3.3.1]-3-nonylamine
- ENDO-9-METHYL-9-AZA-BICYCLO[3.3.1]NON-3-YLAMINE
- ENDO-3-AMINO-9-METHYL-9-AZABICYCLO[3.3.1]NONANE
- 9-METHYL-9-AZA-BICYCLO[3,3,1]NON-3-YL-AMINE
- Endo-9-methyl-9-azabicyclo[3,3,1] nonan-3-amine 76272-56-5
- EMANA(Endo-9-methyl-9-azabicyclo[3,3,1]-nonan-3-amine)
- -3-Amino-9-methyl-9-azabicyclo(3.3.1)-nonane, Granisetron Impurity E (free base)
- ENDO-9-METHYL-9-AZABICYCLO3,3,1-NONAN-3-AMINE
- ENDO-9-METHYL-9-AZABICYCLO[3,3,1]-NONAN-3-AMINE/EMANA
- Ver mais sinónimos
Endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane
CAS:Fórmula:C9H18N2Pureza:97%Cor e Forma:LiquidPeso molecular:154.2526(1R,3r,5S)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine
CAS:Produto ControladoFórmula:C9H18N2Cor e Forma:NeatPeso molecular:154.253Granisetron EP Impurity E (Granisetron USP Related Compound E (Free Form))
CAS:Fórmula:C9H18N2Peso molecular:154.26endo-3-Amino-9-methyl-9-azabicyclo[3,3,1]nonane
CAS:endo-3-Amino-9-methyl-9-azabicyclo[3,3,1]nonanePureza:≥95%Peso molecular:154.25g/molendo-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine (Granisetron Impurity E)
CAS:Produto ControladoImpurity Granisetron EP Impurity E
Applications Granisetron impurity E. An intermediate of Granisetron.
References McCallum, R., et al.: Drugs, 36, 652 (1988), Kaumann, A., et al.: Br. J. Pharmacol., 100, 879 (1990), Mohr, K., et al.: Pharmacol. Toxicol., 70, 198 (1992), Van, W.A., et al.: Nucl. Med. Biol., 21, 41 (1994), Mize, A., et al.: Brain Res., 836, 229 (1999),Fórmula:C9H18N2Cor e Forma:NeatPeso molecular:154.253endo-9-Methyl-9-azabicyclo[3,3,1]nonan-3-amine
CAS:Fórmula:C9H18N2Pureza:97%Cor e Forma:ClearPeso molecular:154.257(3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine
CAS:Granisetron is a drug that belongs to the group of serotonin receptor antagonists. It is used as an antiemetic, mainly in the prevention and treatment of nausea and vomiting caused by cancer chemotherapy and surgery. This drug has been shown to be effective in controlling nausea and vomiting, even when given after chemotherapy or surgical procedures. Granisetron hydrochloride was synthesized in 1988 by chemists at Hoffmann-La Roche. The synthesis was patented in 1990. Potential impurities are not listed on the USP or EP pharmacopeia, but these impurities have been detected during synthesis.
Fórmula:C9H18N2Pureza:Min. 95%Peso molecular:154.25 g/mol







